Search Results
Jun 16, 2026, 12:39 ET Secondary Antibodies Market Size to Reach USD 2.97 Billion by 2033, Growing at a 7.9% CAGR as Standardized Immunoassay Workflows and Biomarker Research Accelerate Global Demand: Verified Market Research
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size By Product (CD3 Bispecific Antibodies, NK-Cell Engagers), By Delivery Method (Intravenous Infusion, Subcutaneous Injection, Intramuscular Injection, Localized Delivery,
More news about: Verified Market Research
Jun 16, 2026, 12:11 ET Country Music Hall of Fame® and Museum to Open New Exhibition, Kenny Chesney: Living in Fast Forward
singer-songwriter project, Be as You Are (Songs from an Old Blue Chair). The chair was prominently featured on the front and back cover of the later CD and in the 2005 music video for "Old Blue Chair."A handwritten Nashville Number System chord chart for "You and Tequila" that was used in the
More news about: Country Music Hall of Fame and Museum
Jun 16, 2026, 10:00 ET AutoRABIT Expands Salesforce DevSecOps Platform into MuleSoft API Governance with Integral Zone Acquisition
Platform environments.Shift-left security and pre-deployment validation: Surface quality, security, and compliance issues earlier in CI/CD and integration delivery workflows.Monitoring, reporting, and operational visibility: Give platform owners, architects, and leaders clearer
More news about: AutoRABIT Holding, Inc.
Jun 16, 2026, 08:52 ET David Armstrong Takes Listeners on a Musical Journey Through All 50 States
June 16, 2026 /PRNewswire/ -- Fifty states, fifty original songs and one musical celebration of America come together in David Armstrong's three-CD collection, My Country 'Tis of Thee. Created in recognition of the United States' 250th anniversary, the project offers listeners a state-by-state
More news about: David Armstrong
Jun 16, 2026, 08:48 ET CTL Launches New OPS Desktop Monitor Alongside New CTL All-in-One Computers with ChromeOS
Without stand: 12.64" h x 21.30" w x 2.32" d, 321 x 541 x 59 mm Contrast: 1000, brightness 250 cd/m2, response time 14-20 msIncluded Chromebox
More news about: CTL Corporation
Jun 16, 2026, 08:23 ET 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
B-cell malignancies and provided the first demonstration that human CD19 CAR-T cells could treat cancer in mice. Dr. June helped demonstrate CD28 co-stimulation as essential for T-cell activation and applied the anti-CD3 and anti-CD28 bead expansion protocol, which has become the global manufacturing
More news about: The Tang Prize Foundation
Jun 16, 2026, 08:00 ET 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
[2] as essential for T-cell activation and applied the anti-CD3 and anti-CD28 bead expansion protocol, which has become the global manufacturing standard for CAR-T cells. He also engineered CAR constructs incorporating the 4-1BB (CD137) co-stimulatory domain and the T-cell receptor-zeta chain (TCR-ζ)
More news about: The Tang Prize Foundation
Jun 16, 2026, 04:26 ET Junkies Coder Launches Agentic AI & Enterprise Modernization Practice to Close the Gap Between AI Ambition and Legacy Reality
Building scalable, cost-efficient foundations engineered for AI and agentic workloads.DevOps & platform engineering - Establishing the CI/CD pipelines, automation, and governance that let teams ship faster and operate safely at scale.By combining these capabilities under one accountable
More news about: Junkies Coder
Jun 15, 2026, 17:58 ET 美納里尼集團於 2026 年歐洲血液學協會 (EHA) 年會公佈 Selinexor 聯合 Ruxolitinib 治療骨髓纖維化的第 3 期 SENTRY 試驗數據
Elacestrant。這是一種口服內分泌治療藥物，適用於治療絕經後女性或成年男性患者，其腫瘤屬雌激素受體 (ER) 陽性、人類表皮生長因子受體 2 (HER2) 陰性，以及帶有 ESR1 突變的晚期或轉移性乳癌，且病情已在接受至少一種內分泌治療後出現進展。 Stemline 亦於美國、歐洲及其他全球地區銷售 Tagraxofusp-erzs。這是一種針對 CD123 的新型標靶治療，適用於治療母細胞性漿細胞樣樹突細胞腫瘤 (BPDCN) 患者。BPDCN 是一種侵襲性血液系統惡性腫瘤。 此外，Stemline 亦於歐洲銷售 Selinexor。Selinexor 是一種用於治療多發性骨髓瘤的 XPO1 抑制劑。 公司目前亦正分別就 Elacestrant
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 16:44 ET Le Groupe Menarini présente les résultats de l'essai clinique SENTRY de phase III sur l'association selinexor-ruxolitinib dans le traitement de la myélofibrose lors du congrès 2026 de l'Association européenne d'hématologie (EHA)
Stemline commercialise également aux États-Unis, en Europe et dans d'autres régions du monde le tagraxofusp-erzs, une nouvelle thérapie ciblée sur le CD123, pour les patients atteints de néoplasme blastique des cellules dendritiques plasmacytoïdes (BPDCN), un cancer hématologique agressif. En outre, Stemline
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 08:20 ET Revolutionizing Cancer Treatment: MAaGI Medical's "i" Series Multimodal Tumor Therapy Technique Globally Debuted
multimodal tumor therapy significantly extends progression-free survival in advanced liver cancer patients and first identified CX3CR1⁺GPR56⁺ tumor-responsive CD8⁺T cells as key functional subsets mediating long-lasting antitumor immunity. The expansion ratio of this cell subset after multimodal treatment is significantly
More news about: MAaGI Medical
Jun 15, 2026, 07:40 ET El Grupo Menarini presenta datos del ensayo de fase 3 SENTRY de selinexor más ruxolitinib en mielofibrosis
terapia endocrina, en Estados Unidos, Europa y otras regiones del mundo. Stemline también comercializa tagraxofusp-erzs, una novedosa terapia dirigida a CD123, para pacientes con neoplasia de células dendríticas plasmocitoides blásticas (BPDCN), un cáncer hematológico agresivo, en Estados Unidos, Europa y
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 07:00 ET Keeper Security Introduces Universal Secrets Sync to Eliminate Credential Drift Across Cloud Environments
Secret Manager using familiar native SDKs and IAM controls – ideal for services performing hundreds of thousands or millions of retrievals per day. For CI/CD pipelines, scripts, internal tools and services running outside the cloud, developers retrieve secrets directly from Keeper Secrets Manager via the KSM
More news about: Keeper Security
Jun 15, 2026, 07:00 ET Il Gruppo Menarini presenta i dati dello studio di fase 3 SENTRY su selinexor più ruxolitinib nella mielofibrosi in occasione del Congresso 2026 dell'Associazione Europea di Ematologia (EHA)
negli Stati Uniti, in Europa e in altre regioni del mondo. Stemline commercializza anche tagraxofusp-erzs, una nuova terapia mirata diretta contro il CD123, per pazienti affetti da neoplasia a cellule dendritiche plasmacitoidi blastiche (BPDCN), un tumore ematologico aggressivo, negli Stati Uniti, in Europa
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 02:01 ET Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
disease (CD)Urinary free cortisol (UFC) normalization is a clinically relevant measure in CD, where chronic cortisol excess is a key driver of morbidity, mortality and quality-of-life burdenPreliminary Phase II Part A data showed UFC normalization in most evaluable adults with CD who completed
More news about: H. Lundbeck A/S
Jun 15, 2026, 01:57 ET Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
disease (CD)Urinary free cortisol (UFC) normalization is a clinically relevant measure in CD, where chronic cortisol excess is a key driver of morbidity, mortality and quality-of-life burdenPreliminary Phase II Part A data showed UFC normalization in most evaluable adults with CD who completed
More news about: H. Lundbeck A/S
Jun 15, 2026, 01:26 ET Menarini Group、European Hematology Association (EHA)の2026年総会にて、骨髄線維症を対象としたセリネキソールとルキソリチニブの併用療法に関する第3相SENTRY試験のデータを発表
Groupの完全子会社であるStemline Therapeutics, Inc.（「Stemline」）は、コマーシャル・ステージにあるバイオ医薬品会社で、患者に革新的ながん治療を提供することに注力しています。Stemlineは、エストロゲン受容体（ER）陽性、ヒト上皮成長因子受容体2（HER2）陰性、ESR1遺伝子変異の進行・転移性乳がんで、少なくとも1ライン以上の内分泌療法後に病勢進行した閉経後女性または成人男性の治療を適応症とする経口内分泌療法剤エラセストラントを、米国、欧州をはじめとする世界各地で販売しています。また、Stemlineは、CD123に対する新規標的治療薬であるタグラクソフスプ・エルツを、ア
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 20:15 ET CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
plasma cells. The Company plans to initiate Phase Ib clinical trials for R/R MM and primary PCL in 2026.About CT1190BCT1190B is a CD19/CD20-targeted allogeneic CAR-T cell therapy developed based on CARsgen's THANK-u Plus® platform. IITs for R/R B-NHL are ongoing. The Company
More news about: CARsgen Therapeutics
Jun 14, 2026, 13:17 ET 메나리니 그룹, 2026 유럽혈액학회(EHA) 학술대회에서 골수섬유증 대상 셀리넥서 및 룩소리티닙 병용요법의 제3상 SENTRY 시험 데이터 발표
양성, 사람 상피세포 성장인자 수용체 2(HER2) 음성, ESR1 변이 진행성 또는 전이성 유방암 치료에 적응증을 보유하고 있다. 스템라인은 또한 미국, 유럽 및 기타 글로벌 지역에서 공격적인 혈액암인 모구성 형질 세포성 수지 세포 신생물(BPDCN) 환자를 대상으로 CD123을 표적으로 하는 새로운 표적 치료제 타그락소푸스프-erzs(tagraxofusp-erzs)를 상업화하고 있다. 또한 스템라인은 유럽에서 다발성 골수종 치료를 위한 XPO1 억제제인 셀리넥서를 상업화하고 있다. 이 회사는 유방암 및 혈액암 적응증에서 각각 엘라세스트란트와
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:13 ET Menarini Group reporta datos del ensayo SENTRY de fase 3 de Selinexor Plus Ruxolitinib en mielofibrosis en el Congreso de la Asociación Europea de Hematología (EHA) 2026
terapia endocrina, en EE. UU., Europa y otras regiones del mundo. Stemline también comercializa tagraxofusp-erzs, una novedosa terapia dirigida contra CD123, para pacientes con neoplasia blástica de células dendríticas plasmocitoides (BPDCN), un cáncer hematológico agresivo, en Estados Unidos, Europa y otras
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:10 ET Grupo Menarini relata dados do Ensaio SENTRY de Fase 3 de Selinexor Plus Ruxolitinibe em mielofibrose no Congresso da Associação Europeia de Hematologia (EHA) 2026
de terapia endócrina, nos EUA, Europa e outras regiões globais. A Stemline também comercializa o tagraxofusp-erzs, uma nova terapia direcionada ao CD123, para pacientes com neoplasia de células dendríticas plasmocitoides blásticas (BPDCN), um câncer hematológico agressivo, nos Estados Unidos, Europa
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:06 ET Die Menarini Group präsentiert auf dem Kongress der European Hematology Association (EHA) 2026 Daten aus der Phase-3-Studie SENTRY zur Kombination von Selinexor und Ruxolitinib bei Myelofibrose
endokriner Therapie in den USA, Europa und anderen globalen Regionen angezeigt ist. Stemline vermarktet auch Tagraxofusp-erzs, eine neuartige, gegen CD123 gerichtete Therapie für Patienten mit blastischen plasmazytoiden dendritischen Zellneoplasien (BPDCN), einer aggressiven hämatologischen Krebserkrankung,
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 07:26 ET Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 13, 2026, 06:33 ET New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.13 Since FDA approval, more than 11,000 patients have been treated with TALVEY ®.TALVEY® is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed
More news about: Johnson & Johnson
Jun 12, 2026, 02:11 ET 亞洲資本俱樂部獲TAKARA LEBEN戰略委任 正式進軍日本房地產市場
Road（明廳片區）活動形式：項目宣講+現場答疑台北專場：日期：2026年6月11日時段：傍晚6:30地點：Oncor響艷都市會所(https://maps.app.goo.gl/Cd1BzPaR3huHq56k9?g_st=il)活動形式：項目宣講+雞尾酒交流會本項目面向海外的可售房源配額有限，所有場次僅接受預約報名，席位先到先得。
More news about: 亞洲資本俱樂部